A Live Attenuated H9N2 Influenza Vaccine Is Well Tolerated and Immunogenic in Healthy Adults
A Live Attenuated H9N2 Influenza Vaccine Is Well Tolerated and Immunogenic in Healthy Adults
复制标题
DOI：
10.1086/596558
复制
发表时间：
2009-03-01
影响因子：
6.4
通讯作者：
Subbarao, Kanta
中科院分区：
文献类型：
--
作者：
Karron, Ruth A.;Callahan, Karen;Subbarao, Kanta
针对具有大流行潜力的禽流感病毒株开发减毒活疫苗（LAIV）是一项重要的公共卫生战略。对50名隔离的成人鼻内注射1或2剂10（7）-TCID（50）剂量的H9 N2 LAIV A/chicken/Hong Kong/G9/97; 41名参与者为H9 N2血清阴性，其中24人接受了2剂。疫苗耐受性良好;疫苗脱落极少。在2次接种后，92%的H9血清阴性参与者的血凝抑制抗体增加>= 4倍，79%的中和抗体增加>= 4倍; 100%的人通过至少1次检测到反应。尽管H9 N2 LAIV的复制受到限制，但2剂疫苗在H9 N2血清阴性成人中具有免疫原性。ClinicalTrials.gov标识符：NCT 00110279。
Development of live attenuated influenza vaccines (LAIV) against avian strains with pandemic potential is an important public-health strategy. Either 1 or 2 10(7)-TCID(50) doses of H9N2 LAIV A/chicken/Hong Kong/G9/97 were administered intra-nasally to 50 adults in isolation; 41 participants were H9N2 seronegative, 24 of whom received 2 doses. The vaccine was well tolerated; vaccine shedding was minimal. After 2 doses, 92% of H9-seronegative participants had >= 4-fold increases in hemagglutination-inhibition antibody, and 79% had >= 4-fold increases in neutralizing antibody; 100% had responses detected by at least 1 assay. Although replication of the H9N2 LAIV was restricted, 2 doses were immunogenic in H9N2-seronegative adults.Trial registration. ClinicalTrials.gov identifier: NCT00110279.